Tempus AI banks $192.5 million from BMS, and $55 million of it goes through a related party
Tempus's new $192.5 million in agreements with Bristol Myers Squibb and Pathos AI confirm what the filing says the business is: per-record data licensing, with $55 million routed through a related party and delivery risk sitting on Tempus.
Vincent Jiang · 2 min read
Bristol Myers Squibb−2.26% — Bristol Myers Squibb, down 2.26 percent today signed away $192.5 million this morning, and most of it buys something unglamorous: rows of de-identified patient records and the software to read them 1. The payments land on Tempus AI+5.07% — Tempus AI, up 5.07 percent today (NASDAQ: TEM), the Chicago precision-medicine data company, in two contracts filed with the SEC on October 23, 2026 1.
The split: one big fixed contract, one per-record
The larger piece is an oncology deal signed October 14: BMS pays Tempus $137.5 million in fixed quarterly installments through December 31, 2031, to license multimodal oncology records, use Tempus's Lens analysis software, and run the data through Pathos's Foundry platform, which BMS licensed separately 1. BMS becomes one of Tempus's largest data customers, the company said 2.
The smaller piece is the one that raises eyebrows. Tempus will license 500,000 de-identified Alzheimer's and neurology records to Pathos AI, a clinical-stage AI drug developer, at 100,000 records a year for five years, at $100 per delivered record: up to $50 million, plus $5 million for updates 1. Tempus has to deliver; Pathos pays only for records that arrive 1.
Of $192.5 million in new payments, $55 million flows through related party Pathos
Data
| Value | |
|---|---|
| BMS oncology SOW | 137.5M |
| Pathos record fees | 50M |
| Pathos updates | 5M |
The related-party thread again
Pathos is not a stranger. Tempus's own 8-K says the two companies overlap in executive leadership and equity ownership, which puts the deal under Tempus's Related Person Transaction Policy; a special committee of disinterested directors approved the terms 1. That is the same channel lawyers flagged on October 22 in our earlier coverage of Tempus buying a company it already owned 12.5% of 1.
BMS, meanwhile, leads Pathos's Series E and takes three-year exclusive neuroscience rights to Foundry 34. Tempus also granted the pair an 18-month lock: it will not license those neurology records to anyone else 1.
What the bulls say, and what is still open
The bull case writes itself: investment-grade pharma money, five-year terms, and an AI platform story now validated by one of the world's largest drugmakers 23. But the receipts say otherwise. This is data licensing, not software: the Pathos fee depends entirely on Tempus delivering records, BMS can walk from the oncology deal on 12 months' notice with a substantial termination fee, and $55 million flowed through a related party 1. Revenue quality, not model quality, is what TEM holders are pricing.
The tell to watch: Tempus's quarterly filings for actual record deliveries under the Neuro Order Form, invoiced monthly 1. Data in the bank settles the argument.
To dig deeper into the fairness fight over Tempus's related-party dealings, read our earlier piece below.
Get Deals by email, free
The acquisitions, rounds and contracts that move AI money. In our daily email, every weekday.
